RT Journal Article
T1 Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study.
A1 Weichenthal, Michael
A1 Ellebaek, Eva
A1 Mangana, Joanna
A1 Asher, Nethanel
A1 Gavrilova, Iva
A1 Kandolf, Lidija
A1 Ugurel, Selma
A1 Hausschild, Axel
A1 Meier, Friedegund
A1 Leiter, Ulrike
A1 Livingstone, Elisabeth
A1 Gebhardt, Christoffer
A1 Gutzmer, Ralf
A1 Ruhlmann, Christina H
A1 Mahncke-Guldbrandt, Louise
A1 Haslund, Charlotte A
A1 Kopec, Sylwia
A1 Teterycz, Paweł
A1 Bender, Marc
A1 Poudroux, Wilfried
A1 Muñoz-Couselo, Eva
A1 Berciano-Guerrero, Miguel-Angel
A1 Shalamanova, Gergana
A1 DePalo, Danielle K
A1 Brozic, Jasmina Maric
A1 Chiarion-Sileni, Vanna
A1 Arance, Anna
A1 Ziogas, Dimitrios
A1 Robert, Caroline
A1 van-de-Velde, Anthonie Obik
A1 Gassama, Awa Aminata
A1 Shapira, Ronnie
A1 BenBetzalel, Guy
A1 Grynberg, Shirly
A1 Ramelyte, Egle
A1 Bertoldo, Fabio
A1 DelPrete, Valerio
A1 Gaudy-Marqueste, Caroline
A1 Mohr, Peter
A1 Dummer, Reinhard
A1 Ascierto, Paolo A
A1 Gogas, Helen
A1 Espinosa, Enrique
A1 Lebbe, Celeste
A1 Rutkowski, Piotr
A1 Haanen, John
A1 Schadendorf, Dirk
A1 Svane, Inge Marie
K1 Adjuvant treatment
K1 Immunotherapy
K1 Melanoma
K1 Resistance
AB Background: Adjuvant immune checkpoint inhibition (ICI) with anti-PD-1 antibodies in high-risk resected melanoma has been shown to improve recurrence-free survival. It is unclear whether prior adjuvant anti-PD-1 therapy is associated with altered response to subsequent ICI treatment in the metastatic setting. Methods: Using data from the European Melanoma Registry (EUMelaReg), we analyzed the efficiency of first-line (1L) ICI in non-resectable or metastatic melanoma after failure from prior adjuvant anti-PD-1 treatment. Both single-agent anti-PD-1 and combined anti-PD-1/CTLA-4 (Ipi/Nivo) 1L regimes were included in the analysis. We identified 389 patients receiving 1L ICI with prior adjuvant anti-PD-1 treatment. The control population was selected from a pool of 3390 PD-1-naive cases by 1:1 matching for the type of 1L ICI and various prognostic factors. As outcome measure, overall remission rates (ORR) were calculated and progression-free survival (PFS) was evaluated by Kaplan-Meier and Cox regression analysis. Results: Out of 389 patients, 303 (77.9 %) received Ipi/Nivo and 86 (22.1 %) anti-PD-1 in 1L. ORR was significantly lower in pre-treated patients (31.4 %) as compared to anti-PD-1 naive patients (48.8 %; p < 0.0001). Kaplan-Meier analysis showed significantly shorter median PFS for pre-treated patients. This applied to both anti-PD-1 and Ipi/Nivo treatment. Patients with early recurrence from adjuvant treatment (during or up to 12 weeks after end of treatment) showed lower ORR (28.5 %) and shorter PFS (3.1 months) than those who recurred later (37.7 % and 6.1 months, respectively). Conclusions: Patients with metastatic melanoma, previously exposed to anti-PD-1 ICI in the adjuvant setting showed significantly lower ORR and shorter PFS to 1L ICI with either Ipi/Nivo or single-agent anti-PD-1 retreatment.
PB Elsevier
SN 0959-8049
YR 2025
FD 2025-03-07
LK https://hdl.handle.net/10668/28501
UL https://hdl.handle.net/10668/28501
LA en
NO Weichenthal M, Ellebaek E, Mangana J, Asher N, Gavrilova I, Kandolf L, et al. Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study. Eur J Cancer. 2025 May 2;220:115339
DS RISalud
RD Aug 24, 2025